Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TT-00420 + toripalimab
- Development stage
- Unknown
- Lead developer
- TransThera Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
TT-00420 + toripalimab is an investigational combination therapy comprising TT-00420 (tinengotinib), a multi-targeted small molecule kinase inhibitor, and toripalimab, a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1). Tinengotinib inhibits multiple kinases involved in tumor growth and angiogenesis, including fibroblast growth factor receptors (FGFRs) and human epidermal growth factor receptor 2 (HER2), among others. Toripalimab blocks the PD-1 immune checkpoint pathway to enhance T-cell mediated antitumor immunity. The combination is being evaluated for safety and efficacy in advanced urological tumors and other solid tumors[1][2][3].
- Other names
- tinengotinib + toripalimab
02
Targets
VEGFR (VEGFR family)JAK2 (Janus kinase 2)AURKA (Aurora kinase A)PDCD1 (Programmed cell death protein 1 receptor)FGFR3 (Fibroblast growth factor receptor 3)JAK1 (Janus kinase 1)ERBB2 (Erb-b2 receptor tyrosine kinase 2)FGFR2 (Keratinocyte growth factor receptor)AURKB (Aurora kinase B)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on TT-00420 + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TT-00420 + toripalimab.